Showing 5081-5090 of 5802 results for "".
- Teledermatology Improves Access to Carehttps://practicaldermatology.com/news/teledermatology-improves-access-to-care/2458577/Teledermatology improves access to care, a new study suggests. In the study of primary care practices in a large California Medicaid managed care plan, those practices that engaged in teledermatology had a 64 percent increase in the fraction of patients vis
- Mission Pharmacal's Lycelle Head Lice Removal Kit Now Available In Pharmacieshttps://practicaldermatology.com/news/mission-pharmacals-lycelle-head-lice-removal-kit-now-available-in-pharmacies/2458578/Mission Pharmacal's former prescription Lycelle Head Lice Removal Kit will now be available without a prescription. Lycelle is a treatment for the elimination of head lice and their eggs. Lycelle uses a non-pesticidal formulation that is safe for use with children as young as two years o
- Global Derm Market Set to Soar Through 2022https://practicaldermatology.com/news/global-derm-market-set-to-soar-through-2022/2458579/The global dermatology market is set to boom from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%,
- Galderma Gives Chefs a Hand with New Excipial Partnershiphttps://practicaldermatology.com/news/galderma-gives-chefs-a-hand-with-new-excipial-partnership/2458582/Galderma Laboratories, L.P., maker of Excipial, is teaming up with the American Culinary Federation to help chefs treat their dry hands. Professional chefs spend about 14 hours a day in the kitchen, prepping food and washing their hands,
- Largest Independent US Psoriasis Registry to Track Safety of Ixekizumab Biologic Treatmenthttps://practicaldermatology.com/news/largest-independent-us-psoriasis-registry-to-track-safety-of-ixekizumab-biologic-treatment/2458583/The Corrona Psoriasis Registry will track the drug safety reporting for ixekizumab, Eli Lilly and Company's biologic medication that was recently approved for the treatment of moderate-to-severe plaque psoriasis. The registry is a joint collaboration between the National Psoriasis Foundation
- Study IDs Rosacea-Alzheimers Linkhttps://practicaldermatology.com/news/study-ids-rosacea-alzheimers-link/2458584/Rosacea may be linked to an increased risk of dementia—in particular Alzheimer’s disease, new research suggests. This risk was highest in older patients and in patients where rosacea was diagnosed by a hospital dermatologist. The new findings are published in the </
- Vitiligo and Gray Hair Treatment Breakthrough? Study IDs Mechanism That Controls Skin and Hair Colorhttps://practicaldermatology.com/news/vitiligo-and-gray-hair-treatment-breakthrough-study-ids-mechanism-that-controls-skin-and-hair-color/2458587/A pair of molecular signals controls skin and hair color in mice and humans - and could be targeted by new drugs to treat skin pigment disorders like vitiligo, according to a report out of NYU Langone Medical Center in New York City. Finding ways to activate these pathways could lea
- Modernizing Medicine's Dermatology-specific EHR System Top Rated by KLAShttps://practicaldermatology.com/news/modernizing-medicines-dermatology-specific-ehr-system-top-rated-by-klas/2458591/Modernizing Medicine, Inc.’s EMA Dermatology has been rated the top electronic health record (EHR) system for dermatologists in the inaugural KLAS “Ambulatory Specialty 2016 One Size Does Not Fit All Performance Report.” KLAS, best known for its “Best in KLAS: Soft
- Valeant Names Joseph C. Papa as Chairman and CEOhttps://practicaldermatology.com/news/valeant-names-joseph-c-papa-as-chairman-and-ceo/2458593/Valeant Pharmaceuticals International, Inc's Board of Directors has named Joseph C. Papa to become its Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. He will join Valeant from Perrigo Company plc, a leading global health
- Allergan Acquires Topokine Therapeuticshttps://practicaldermatology.com/news/allergan-acquires-topokine-therapeutics/2458596/Allergan has acquired Topokine Therapeutics, the makers of XAF5 ointment for the reduction of undereye bags and other topical medicines for fat reduction. Under the terms of the agreement, Allergan acquired Topokin